Is PURPLE BIOTECH LTD. (PPBT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.7% / 30% | 171.9% / 30% | 5.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 3.7% / 33% | 171.9% / 33% | 5.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.5% / 33% | 23.0% / 33% | 0.7% / 33% | N/A | ✓ HALAL |
| S&P | 3.7% / 33% | 171.9% / 33% | 5.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.5% / 33% | 23.0% / 33% | 0.7% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -124.5% | |
| Return on Assets (ROA) | -16.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$14M |
| Free Cash Flow | -$14M |
| Total Debt | $183,000 |
| Debt-to-Equity | 2.5 |
| Current Ratio | 1.3 |
| Total Assets | $37M |
Price & Trading
| Last Close | $3.99 |
| 50-Day MA | $5.20 |
| 200-Day MA | $11.22 |
| Avg Volume | 13K |
| Beta | -0.7 |
|
52-Week Range
$3.65
| |
About PURPLE BIOTECH LTD. (PPBT)
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PURPLE BIOTECH LTD. (PPBT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PURPLE BIOTECH LTD. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PURPLE BIOTECH LTD.'s debt ratio?
PURPLE BIOTECH LTD.'s debt ratio is 3.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.5%.
What are PURPLE BIOTECH LTD.'s key financial metrics?
PURPLE BIOTECH LTD. has a market capitalization of $6M. Return on equity stands at -124.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.